DZ 697b

Drug Profile

DZ 697b

Alternative Names: DA-697b; DZ-697b

Latest Information Update: 15 May 2008

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antiplatelets; Antithrombotics
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 13 May 2008 Discontinued - Phase-I for Thrombosis in Europe (PO)
  • 13 May 2008 Discontinued - Phase-I for Thrombosis in Japan (PO)
  • 13 May 2008 Discontinued - Phase-I for Thrombosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top